162 related articles for article (PubMed ID: 17033223)
1. [Problems associated with molecular targeted drugs for cancer].
Kawaishi M; Koizum F; Nishio K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1373-9. PubMed ID: 17033223
[TBL] [Abstract][Full Text] [Related]
2. [Molecular-target drug].
Sone S; Yano S; Nishioka Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
[TBL] [Abstract][Full Text] [Related]
3. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
4. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
5. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
Lehne G; Bjørheim J; Saeter G
Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
[TBL] [Abstract][Full Text] [Related]
6. [Molecular targeted therapy for cancer].
Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance in cancer: its mechanism and its modulation.
Pauwels EK; Erba P; Mariani G; Gomes CM
Drug News Perspect; 2007; 20(6):371-7. PubMed ID: 17925891
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.
Loni L; Del Tacca M; Danesi R
Br J Cancer; 2001 Nov; 85(10):1425-31. PubMed ID: 11720423
[TBL] [Abstract][Full Text] [Related]
9. [Dose escalation strategies of molecular target drugs].
Tahara M; Sasaki Y
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1759-63. PubMed ID: 11057331
[TBL] [Abstract][Full Text] [Related]
10. [Current status and problems of tailor-made medicine in anticancer therapy].
Miya T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):515-9. PubMed ID: 17431334
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
12. [Cancer chemotherapy in patients older than 75 years old--from the aspect of clinical pharmacology].
Tanaka K; Okumura K
Gan To Kagaku Ryoho; 1998 Jun; 25(7):995-9. PubMed ID: 9644313
[TBL] [Abstract][Full Text] [Related]
13. [Current problems in development of new anticancer agents for new molecular targets].
Nishii K
Gan To Kagaku Ryoho; 1996 Jan; 23(2):211-8. PubMed ID: 8611049
[TBL] [Abstract][Full Text] [Related]
14. Resistance to chemotherapy in cancer: a complex and integrated cellular response.
Mellor HR; Callaghan R
Pharmacology; 2008; 81(4):275-300. PubMed ID: 18259091
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic markers of perifosine efficacy.
Hennessy BT; Lu Y; Poradosu E; Yu Q; Yu S; Hall H; Carey MS; Ravoori M; Gonzalez-Angulo AM; Birch R; Henderson IC; Kundra V; Mills GB
Clin Cancer Res; 2007 Dec; 13(24):7421-31. PubMed ID: 18094426
[TBL] [Abstract][Full Text] [Related]
17. CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
[TBL] [Abstract][Full Text] [Related]
18. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
